Shots:
- Japan’s MHLW has granted ODD to mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- Mosliciguat (dry powder inhaler) is being evaluated in an ongoing global P-II (PHocus) trial against PBO among ~120 PH-ILD adults, with trial design to be presented at ERS Congress 2025
- Mosliciguat is an sGC activator that works independently of heme & nitric oxide to promote vasodilation, reverse vascular remodeling & reduce inflammation as well as apoptosis, which showed reduced pulmonary vascular resistance by up to 38% in the P-Ib (ATMOS) study
Ref: Pulmovant| Image: Pulmovant & Roivant | Press Release
Related News:- TOLREMO Therapeutics’ TT125-802 Secures 2 US FDA’s Fast-Track Designation for NSCLC with EGFR & KRAS-G12C Mutation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
